pI: 8.8761 |
Length (AA): 372 |
MW (Da): 41345 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
NA% percentile | Procyclic. | Siegel TN |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_147203)
Species | Accession | Gene Product |
---|---|---|
Leishmania braziliensis | LbrM.28.0460 | ribonuclease II-like protein, putative |
Leishmania donovani | LdBPK_280310.1 | DIS3-like exonuclease, putative |
Leishmania infantum | LinJ.28.0310 | ribonuclease II-like protein, putative |
Leishmania major | LmjF.28.0450 | ribonuclease II-like protein, putative |
Leishmania mexicana | LmxM.28.0450 | ribonuclease II-like protein, putative |
Trypanosoma brucei gambiense | Tbg972.11.9460 | exosome complex exonuclease RRP44, putative |
Trypanosoma brucei | Tb927.11.8290 | DIS3-like exonuclease, putative |
Trypanosoma brucei | Tb11.v5.1053 | DIS3-like exonuclease, putative |
Trypanosoma congolense | TcIL3000.11.8840 | DIS3-like exonuclease, putative |
Trypanosoma cruzi | TcCLB.509595.50 | DIS3-like exonuclease, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.01.0260 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.01.0260 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb11.01.0260 | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb11.01.0260 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.